Xilio Therapeutics (XLO) Equity Ratio (2020 - 2026)

Xilio Therapeutics has disclosed Equity Ratio across 7 years of filings, most recently posting 0.44 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.44, up 330.12% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.44 (up 330.12% YoY), and the FY2025 annual result was 0.23, down 7.9% from the prior year.
• Equity Ratio came in at 0.44 for Q1 2026 at Xilio Therapeutics, up from 0.23 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.85 in Q1 2022 to a low of 0.06 in Q3 2025.
• The 5-year median for Equity Ratio is 0.44 (2026), against an average of 0.47.
• Across the five-year window, Equity Ratio tumbled 121.55% in 2025 and jumped 330.12% in 2026, its largest moves.
• Xilio Therapeutics' Equity Ratio stood at 0.76 in 2022, then retreated by 20.38% to 0.6 in 2023, then slumped by 59.04% to 0.25 in 2024, then dropped by 7.9% to 0.23 in 2025, then surged by 94.59% to 0.44 in 2026.
• The last three Equity Ratio figures came in at 0.44 (Q1 2026), 0.23 (Q4 2025), and 0.06 (Q3 2025), per Business Quant data.